Immunogenicity and safety study of 23-valent pneumococcal polysaccharide vaccine revaccination among elderly individuals aged 60–70 years in Shanghai, China

Immunogenicity and safety study of 23-valent pneumococcal polysaccharide vaccine revaccination among elderly individuals aged 60–70 years in Shanghai, China

BackgroundTo understand the immunogenicity and safety of the 23-valent pneumococcal polysaccharide vaccine in elderly individuals aged 60–70 years in Shanghai after revaccination.MethodsA total of 330 elderly people aged 60–70 years were recruited to study the immunogenicity and safety of PPSV23 rev...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jing Qiu, Zhi Li, Fang Huang, Zhuoying Huang, Xiufang Liang, Juan Li, Yuting Liao, Xiang Guo, Xiaodong Sun
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Immunology
Subjects:	elderly revaccination 23-valent pneumococcal polysaccharide vaccine immunogenicity safety
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1623611/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Immunogenicity, Safety, and Clinical Eﬀectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine in Patients With Spondyloarthritis (Preliminary Data)
by: M. M. Baranova, et al.
Published: (2022-04-01)

Immunogenicity of Pneumococcal Polysaccharide Vaccine in patients with rheumatoid arthritis
by: B. Ts. Batozhargalova, et al.
Published: (2024-09-01)

The immunogenicity and safety of an inactivated quadrivalent influenza vaccine and a 23-valent pneumococcal polysaccharide vaccine in individuals with chronic diseases
by: Wanqin Tang, et al.
Published: (2025-08-01)

Correction: The immunogenicity and safety of an inactivated quadrivalent influenza vaccine and a 23-valent pneumococcal polysaccharide vaccine in individuals with chronic diseases
by: Frontiers Production Office
Published: (2025-08-01)

INVESTIGATION OF IMMUNOGENICITY AND SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
by: G. M. Tarasova, et al.
Published: (2018-09-01)

Immunogenicity, Tolerability, and Clinical Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine in Patients with Systemic Lupus Erythematosus
by: G. M. Tarasova, et al.
Published: (2020-08-01)

Safety and efficacy of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus
by: G. M. Tarasova, et al.
Published: (2021-06-01)

Impact of Chemotherapy on Vaccine Immunogenicity and Revaccination Response of Acute Lymphoblastic Leukemia—A Systematic Review and Meta-Analysis
by: Yuyuan Zeng, et al.
Published: (2025-06-01)

Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience
by: N. L. Chernaya, et al.
Published: (2012-02-01)

Preventive effects of 23-valent pneumococcal polysaccharide vaccine on community-acquired pneumonia hospitalization in older individuals in China: A case-control study
by: Na Liu, et al.
Published: (2024-12-01)

ASSESSMENT OF THE IMMUNOGENICITY AND SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH RHEUMATIC DISEASES
by: M. S. Naumtseva, et al.
Published: (2016-02-01)

The Safety and Immunogenicity of a 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) in Infants: A Double-Blind, Randomized, Phase III Trial
by: Zhiqiang Xie, et al.
Published: (2024-12-01)

PHARMACOECONOMIC ASSESSMENT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN IMMUNIZATION OF CHILDREN IN RUSSIAN FEDERATION
by: A. V. Rudakova, et al.
Published: (2014-01-01)

EXPERIENCE OF APPLICATION AND SAFETY ASSESSMENT OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN UNDER-5 CHILDREN
by: M. V. Fedoseenko, et al.
Published: (2014-09-01)

Seroepidemiological Study of Measles Virus among Young Adults: Response to Revaccination
by: Baghdad Science Journal
Published: (2014-12-01)

Epidemiological and etiological characteristics of community-acquired pneumonia in conscripts in the modern period. Comparative evaluation of the effectiveness of pneumococcal vaccines
by: P. V. Kulikov, et al.
Published: (2019-05-01)

PNEUMOCOCCAL INFECTION VACCINAL PREVENTION EFFICACY IN CHILDREN USING PNEUMOCOCCAL CONJUGATED 7-VALENT VACCINE
by: N. L. Chernaya, et al.
Published: (2013-01-01)

Economic Evaluation of Transitioning to the 20-Valent Pneumococcal Conjugate Vaccine in the Dutch Paediatric National Immunisation Programme
by: Esra Çakar, et al.
Published: (2025-02-01)

The Use of 23-Valent Pneumococcal Polysaccharide Vaccine in Patients with Rheumatoid Arthritis
by: M. S. Naumtseva, et al.
Published: (2015-08-01)

Immunogenicity, safety and tolerability of 15-valent pneumococcal conjugate vaccine (V114) compared to 13-valent pneumococcal conjugate vaccine (PCV-13) in healthy infants: A systematic review and meta-analysis
by: Muhammad Zain Ul Haq, et al.
Published: (2025-06-01)

IMMUNOGENICITY AND SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS OF A TWO-YEAR FOLLOW-UP STUDY
by: M. S. Naumtseva, et al.
Published: (2017-01-01)

Clinical Efficacy of Pneumococcal Conjugate 13-valent Vaccine in Young Children
by: S. M. Kharit, et al.
Published: (2016-12-01)

EFFICACY AND SAFETY OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: M. S. Naumtseva, et al.
Published: (2015-05-01)

The safety of BCG revaccination in the context of COVID-19
by: Adriana Sánchez-García, et al.
Published: (2023-12-01)

Pharmacoeconomic aspects of vaccination against Pneumococcal Infection in Russia
by: A. V. Rudakova, et al.
Published: (2014-09-01)

Immunogenicity and Safety of Pneumococcal Vaccines Co-Administered with Common Travel Vaccines in Adults: A Systematic Review
by: Raziyeh Niyati, et al.
Published: (2025-06-01)

Revaccination against COVID-19: Current Status of the Problem
by: N. P. Andreeva, et al.
Published: (2024-05-01)

The Experience of Vaccination of a Patient With Juvenile Idiopathic Arthritis With Frequent Respiratory Infections With a Pneumococcal 13-Valent Conjugate Vaccine During Methotrexate Therapy
by: Margarita A. Soloshenko, et al.
Published: (2017-10-01)

The New Era of Pneumococcal Vaccination in Adults: What Is Next?
by: Lale Ozisik
Published: (2025-05-01)

A cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the prevention of pneumococcal disease among Mexican adults aged ≥60 years
by: Jose Luis Huerta, et al.
Published: (2025-08-01)

Immunization With a Pneumococcal Polysaccharide Vaccine in Children With Juvenile Idiopathic Arthritis Without Systemic Manifestations: a Prospective Study
by: Ekaterina I. Alexeeva, et al.
Published: (2018-01-01)

Experience of Vaccination of a Patient with Systemic Juvenile Idiopathic Arthritis (sJIA) with a 13-Valent Pneumococcal Conjugate Vaccine, prior to the Appointment of Therapy with Tocilizumab, an Anti-IL-6-Receptor Monoclonal Antibody
by: Daria D. Vankova, et al.
Published: (2018-10-01)

Suspected adverse events following immunization associated with seperate/combined administration of 13-valent pneumococcal polysaccharide conjugate vaccine and oral pentavalent human rotavirus live attenuated vaccine in age-eligible children in a district of Shanghai
by: CHEN Jinyan, et al.
Published: (2025-03-01)

Analysis of the humoral and cell-mediated immune response in heterologous and homologous SARS-CoV-2 revaccination
by: O. M. Drapkina, et al.
Published: (2023-11-01)

13-valent Pneumococcal Conjugate Vaccine and Haemophilus Influenzae-Tetanus Toxoid Conjugate Vaccine in Patient with Systemic Juvenile Idiopathic Arthritis Receiving Tocilizumab: Clinical Case
by: Ekaterina I. Alekseeva, et al.
Published: (2019-09-01)

Immune persistence of a single dose of 23-valent pneumococcal polysaccharide vaccine: A 6-year follow-up
by: Lili Huang, et al.
Published: (2025-12-01)

13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: V. K. Tatochenko, et al.
Published: (2012-03-01)

IAPSM’s Position Paper on Pneumococcal Vaccine (PCV) for Adult Immunization in India
by: Chythra R. Rao, et al.
Published: (2024-12-01)

Pneumococcal Vaccine in Patients with Recurrent Infections
by: Mariana de Gouveia-Pereira Pimentel, et al.
Published: (2025-06-01)

EFFECTIVENESS OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE: EMERGING DATA FROM INVASIVE PNEUMOCOCCAL DISEASE, PNEUMONIA, ACUTE OTITIS MEDIA AND NASOPHARYNGEAL CARRIAGE
by: Ralf Rene Reinert, et al.
Published: (2012-06-01)